# US 2025/0152682 A1 · Liquid botulinum toxin formulation and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152682 A1
- Document ID: US20250152682A1
- Status: Published application
- Kind: A1
- Application number: 18/838,555
- Filed: 2023-02-14
- Published: 2025-05-15
- Earliest claimed: 2022-02-15
- Assignees: MERZ PHARMA GmbH & CO. KGaA
- Applicants: Merz Pharma GmbH & Co. Kgaa
- Inventors: Karl-Heinz EISELE; Klaus FINK; Harold V. TAYLOR; Claudia JATZKE; Katja KÜHBACH
- Web page: https://patentgrep.com/patent/US20250152682A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/4893: {Botulinum neurotoxin (3.4.24.69)}
- A61K 8/44: Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61K 8/66: Enzymes
- A61K 38/385: {Serum albumin}
- A61K 47/02: Inorganic compounds
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61P 13/06: Anti-spasmodics
- A61Q 19/00: Preparations for care of the skin
- C12Y 304/24069: Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- C12Y: ENZYMES

## Abstract

The present invention relates to a liquid formulation comprising (i) botulinum toxin, (ii) human serum albumin (HSA), and optionally (iii) a tonicity agent and/or (iv) a buffering agent. In one aspect, the liquid formulation is characterized by a very low iron ion concentration. In another aspect, liquid formulation is characterized by the absence or very low concentration of tryptophan and/or N-acetyl-tryptophan. According to the present invention, the liquid formulation can be prepared by a method comprising the steps of contacting human serum albumin with a chelating agent to obtain a mixture and removing the chelating agent from the mixture. Furthermore, the present invention relates to the use of the liquid formulation in the treatment of therapeutic indications and cosmetic conditions.

## Claims

### Claim at position 1

-15. (canceled)

### Claim 16

A liquid formulation, comprising
(i) botulinum toxin and
(ii) human serum albumin,
wherein the liquid formulation contains Fe3+ ions in a concentration of less than 1 μM.

### Claim 17 (depends on 16)

The liquid formulation of claim 16, wherein the liquid formulation contains Fe3+ ions in a concentration of less than 500 nM.

### Claim 18 (depends on 16)

The liquid formulation of claim 16, wherein the liquid formulation contains Fe3+ ions in a concentration of less than 250 nM.

### Claim 19 (depends on 16)

The liquid formulation of claim 16, wherein the liquid formulation is prepared by a method comprising the following steps:
(a) contacting human serum albumin with a chelating agent to obtain a mixture of human serum albumin and the chelating agent, and
(b) removing the chelating agent from the mixture.

### Claim 20 (depends on 19)

The liquid formulation of claim 19, wherein, in step (a), a human serum albumin starting material is contacted with a chelating agent to obtain a mixture of the human serum albumin starting material and the chelating agent and, in step (b), the chelating agent is removed from the mixture to obtain a pre-treated human serum albumin material and, in a further step (c), botulinum toxin is mixed with the pre-treated human serum albumin material.

### Claim 21 (depends on 19)

The liquid formulation of claim 19, wherein, in step (a), a liquid pre-formulation comprising botulinum toxin and human serum albumin is contacted with the chelating agent to obtain a mixture of the liquid pre-formulation and the chelating agent and, in step (b), the chelating agent is removed from the mixture to obtain the liquid formulation.

### Claim 22 (depends on 16)

The liquid formulation of claim 16, wherein the human serum albumin is present in the liquid formulation in an amount of 0.001-1.00% w/v.

### Claim 23 (depends on 16)

The liquid formulation of claim 16, wherein the liquid formulation further comprises:
(iii) a tonicity agent,
or wherein the liquid formulation further comprises:
(iii) a tonicity agent, wherein the tonicity agent is present in the liquid formulation in an amount of 0.01-2.0% w/v, or wherein the tonicity agent is sodium chloride, or wherein the tonicity agent is sodium chloride and is present in the liquid formulation in an amount of 0.01-2.0% w/v.

### Claim 24 (depends on 16)

The liquid formulation of claim 16, wherein the liquid formulation further comprises:
(iv) a buffering agent.

### Claim 25 (depends on 24)

The liquid formulation of claim 24, wherein the buffering agent is present in the liquid formulation in a concentration of 1-100 mM.

### Claim 26 (depends on 24)

The liquid formulation of claim 24, wherein the buffering agent is an amino acid, phosphate, or a mixture thereof.

### Claim 27 (depends on 24)

The liquid formulation of claim 24, wherein the buffering agent is histidine, phosphate, or a mixture thereof, and the histidine and phosphate are present in the liquid formulation in a concentration of 1-100 mM.

### Claim 28 (depends on 16)

A method of treating a cosmetic condition, neuromuscular diseases, pain, sialorrhea, hyperhidrosis, urological disorders, and neurological disorders comprising the steps of: administering the liquid formulation of claim 16 to a patient in need thereof.

### Claim 29

A liquid formulation, comprising
(i) botulinum toxin and
(ii) human serum albumin,
wherein the liquid formulation contains no or no more than 50 μM tryptophan and N-acetyl-tryptophan.

### Claim 30 (depends on 29)

The liquid formulation of claim 29, wherein the liquid formulation contains Fe3+ ions in a concentration of less than 1000 nM.

### Claim 31 (depends on 29)

A method for preparing a liquid formulation according to claim 29, wherein the method comprises the following steps:
purifying a human serum albumin starting material to obtain a purified human serum albumin material,
mixing the obtained purified human serum albumin with botulinum toxin and optionally further components to obtain the liquid formulation,
wherein the purifying step is carried out by subjecting the human serum albumin starting material or the liquid composition comprising botulinum toxin and human serum albumin to dialysis, diafiltration, ultrafiltration, ion exchange chromatography, affinity chromatography, hydrophobic interaction chromatography, field flow fractionation or precipitation.

### Claim 32 (depends on 31)

The method of claim 31, wherein the chelating agent is selected from the group consisting of aminopolycarboxylic acids having three to six carboxylic acid functional groups, citrate, porphyrins, N,N,N′,N′-tetrakis(2-pyridinylmethyl)-1,2-ethanediamine (TPEN), triethylenetetramine (TETA), and mixtures thereof.

### Claim 33 (depends on 31)

The method of claim 31, wherein the purifying step comprises:
contacting a human serum albumin starting material with a chelating agent to obtain a mixture of the human serum albumin starting material and the chelating agent, and
removing the chelating agent from the mixture to obtain a chelating agent-treated purified human serum albumin material,
wherein the step of contacting is carried out such that the concentration of the chelating agent in mixture is 1 mM to 500 mM, and/or the removal of the chelating agent is carried out by dialysis, crossflow filtration or ultrafiltration.

### Claim 34 (depends on 29)

A method for preparing a liquid formulation according to claim 29, wherein the method comprises the following steps:
purifying a liquid composition comprising botulinum toxin and human serum albumin to obtain a purified liquid composition,
mixing the obtained purified liquid composition with further components to obtain the liquid formulation,
wherein the purifying step is carried out by subjecting the human serum albumin starting material or the liquid composition comprising botulinum toxin and human serum albumin to dialysis, diafiltration, ultrafiltration, ion exchange chromatography, affinity chromatography, hydrophobic interaction chromatography, field flow fractionation or precipitation.

### Claim 35 (depends on 34)

The method of claim 34, wherein the purifying step comprises:
contacting a liquid composition comprising botulinum toxin and human serum albumin with the chelating agent to obtain a mixture of the liquid composition and the chelating agent, and
removing the chelating agent from the mixture to obtain a chelating agent-treated purified liquid formulation,
wherein the step of contacting is carried out such that the concentration of the chelating agent in mixture is 1 mM to 500 mM, and/or the removal of the chelating agent is carried out by dialysis, crossflow filtration or ultrafiltration.

### Claim 36 (depends on 34)

The method of claim 34, wherein the chelating agent is selected from the group consisting of aminopolycarboxylic acids having three to six carboxylic acid functional groups, citrate, porphyrins, N,N,N′,N′-tetrakis(2-pyridinylmethyl)-1,2-ethanediamine (TPEN), triethylenetetramine (TETA), and mixtures thereof.

### Claim 37 (depends on 36)

The method of claim 36, wherein the chelating agent is an aminopolycarboxylic acid of general formula (I):
(HO2CCH2)2N—R—N(CH2CO2H)2 (I),
wherein R comprises no carboxylic acid group or one or two carboxylic acid groups.

### Claim 38 (depends on 37)

The method of claim 37, wherein the aminopolycarboxylic acid is selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(b-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), 1,2-bis(o-aminophenoxy) ethane-N,N,N′,N′-tetraacetic acid (BAPTA), diethylenetriaminepentaacetic acid (DTPA), triethylenetetraminehexaacetate (TTHA), and mixtures thereof.

### Claim 39 (depends on 29)

The liquid formulation of claim 29, wherein the botulinum toxin is a botulinum neurotoxin of serotype A, free of complexing proteins, and is present at a concentration of 1-1000 U/ml.

### Claim 40 (depends on 29)

A method of treating neuromuscular diseases, pain, sialorrhea, hyperhidrosis, urological disorders, and neurological disorders comprising the steps of: administering the liquid formulation of claim 29 to a patient in need thereof.

### Claim 41 (depends on 29)

A method of treating a cosmetic condition comprising the steps of: administering the liquid formulation of claim 29 to a patient in need thereof.

### Claim 42

A liquid formulation, comprising
(i) botulinum toxin and
(ii) human serum albumin,
wherein the liquid formulation is prepared by a method comprising the following steps:
(a) contacting human serum albumin with a chelating agent to obtain a mixture of human serum albumin and the chelating agent, and
(b) removing the chelating agent from the mixture.
